Our study further corroborates these findings, indicating that SUVmax derived from 68Ga-PSMA-11 PET/MR, with an optimal cut-off of 7.67, can effectively evaluate Ki-67 expression in prostate cancer patients. The gene discussed is MKI67; the disease is prostate carcinoma.